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background:  Obese-insulin resistance due to high-fat diet (HFD) consumption is associated with left ventricular (LV) dysfunction and at risk of 
myocardial infarction. Although vildagliptin (V) and metformin (M) exert cardioprotection, their effects on the hearts under obese-insulin resistance 
and ischemia-reperfusion (I/R) injury are still unknown. We hypothesized that combined V+M provides better cardioprotection against I/R injury than 
monotherapy in obese-insulin resistant rats.
Method: Rats were fed either HFD or normal diet for 12 weeks. Each group was divided into 4 subgroups to receive V (3 mg/kg), M (30 mg/kg), V+M 
or vehicle for 21 days. Ischemia due to left anterior descending artery ligation was allowed for 30 min, followed by 120-min reperfusion. Heart rate 
variability (HRV), LV function, infarct size, metabolic and biochemical parameters and mitochondrial function were determined.
results: HFD impaired insulin sensitivity, HRV and LV function. V, M and V+M improved all parameters. Under I/R condition, all treatments 
improved LV function, reduced infarct size, Bax/Bcl-2 ratio, improved mitochondrial function (Figure) and intracellular calcium transient. Only V+M 
reduced mortality rate, arrhythmia score, delayed time to first VT/VF onset, increased p-Connexin 43 in HFD rats.
Conclusion: V, M attenuate insulin resistance and cardiac I/R injury. However, V+M provides better cardioprotection than monotherapy by reducing 
mortality rate and arrhythmias.
